OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
ACADIA Pharmaceuticals Inc. · Hyperphagia in Prader-Willi Syndrome
Phase 3
Enrolling by invitation
160
2025-12
Industry sponsor intelligence
ACADIA Pharmaceuticals Inc.Clinical Pipeline.
Lead-sponsor view of ACADIA Pharmaceuticals Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 2
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 165
Pipeline overview
Programs by phase and activity.
Velocity
ACADIA Pharmaceuticals Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 20
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Carbetocin → | 2 | 0 | 0 | 2 | 0 | 2 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
ACADIA Pharmaceuticals Inc. · Hyperphagia in Prader-Willi Syndrome
Phase 3
Active, not recruiting
170
2025-09
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All ACADIA Pharmaceuticals Inc. studies.
This page groups studies where ACADIA Pharmaceuticals Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first